-- 週三下午晚些時候，醫療保健類股走高，紐約證券交易所醫療保健指數上漲0.3%，道富醫療保健精選行業SPDR ETF（XLV）上漲0.2%。 iShares生物科技ETF（IBB）上漲2.1%。 在公司新聞方面，DaVita（DVA）股價飆升超過21%，此前德意志銀行將該股評級從“持有”上調至“買入”，並將目標價從126美元上調至220美元。此前一天，該公司公佈了好於預期的第一季業績。
Related Articles
Research
Research Alert: Payc Delivers Q1 Beat, Returns $1b+ To Shareholders Despite Growth Deceleration
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PAYC delivered solid Q1 2026 results with revenue of $572M (+8%) and non-GAAP EPS of $3.15 (+13%), beating consensus by $0.16, while adjusted EBITDA margin expanded to 48.2%. Recurring revenue growth of 9% reflects moderation from historical double-digit expansion, consistent with management's conservative 2026 guidance of 6%-7% revenue growth. We believe PAYC's AI automation solutions including Beti, GONE, and IWant position the company as a differentiated leader, driving higher client engagement and satisfaction. Management emphasized confidence in long-term growth opportunities, noting only 5% of the total addressable market is currently served. Capital allocation remained aggressive with $1.06B in share repurchases and $17.7M in dividends, totaling over $1.08B in returns despite taking on $675M in new debt. Continued operational leverage and market share gains expected as the company leverages its employee-first technology platform to capture untapped market opportunity.
$PAYC
Mining & Metals
5N Plus Posts Higher Profit, Revenue for First Quarter; Adjusted EBITDA Guidance Maintained
5N Plus (VNP.TO) after trade Wednesday said its first-quarter profit and revenue rose year-over year.The company earned US$17.8 million, or US$0.20 per share, in the period, up from US$9.6 million, or US$0.11, a year prior. FactSet expected US$0.14 per share.Revenue rose to US$117.9 million from US$88.9 million a year ago. FactSet projected US$104 million. The company said the increase was mainly driven by higher volumes under Specialty Semiconductors and higher bismuth-based product pricing under Performance Materials.The company added that it is maintaining its adjusted EBITDA outlook range at between US$100 and US$105 million in 2026."In 2026, 5N+ continues to expect demand in Specialty Semiconductors to remain strong, supported by structural expansion across its core end markets, with particular strength in its strategic sectors of terrestrial renewable energy and space solar power. These trends, combined with the company's position as the leading global supplier of ultra-high-purity specialty semiconductor compounds outside China, are expected to continue supporting long-term growth in this segment," 5N said.The company's shares closed up $0.85 to $36.05 on the Toronto Stock Exchange.
$VNP.TO
Australia
MKS Q1 Non-GAAP Earnings, Revenue Rise; Shares Jump After Hours
MKS (MKSI) reported Q1 non-GAAP earnings late Wednesday of $2.30 per diluted share, up from $1.71 a year earlier.Analysts surveyed by FactSet expected $2.04.Revenue in the three months ended March 31 rose to $1.08 billion from $936 million a year earlier.Analysts polled by FactSet expected $1.05 billion.MKS expects Q2 non-GAAP EPS of $2.90, plus or minus $0.30, on revenue of $1.2 billion, plus or minus $40 million.Analysts expect EPS of $2.37 on revenue of $1.09 billion.MKS shares jumped 10% in after-hours trading.
$MKSI